European Association for the Study of the Liver (EASL) Congress 2023

Vienna, Austria 21 June 2023 - 24 June 2023

Age, tumour size predict post-TACE complications in HCC patients

21 Jul 2023 by

In patients with hepatocellular carcinoma (HCC), most complications following transarterial chemoembolization (TACE) involve minor postembolization syndrome, reveals a study presented at EASL 2023. The incidence of major complications is high at 25 percent, with a 1.8-percent death rate.

Age, tumour size predict post-TACE complications in HCC patients

21 Jul 2023

Mycophenolate mofetil prompts remission better than azathioprine in autoimmune hepatitis

20 Jul 2023 by

Among patients with treatment-naïve autoimmune hepatitis, more of those who receive mycophenolate mofetil achieve remission than those who receive azathioprine, as shown in the results of the CAMARO trial.

Mycophenolate mofetil prompts remission better than azathioprine in autoimmune hepatitis

20 Jul 2023

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

20 Jul 2023 by

The addition of simvastatin to a nonselective beta blocker results in better survival among cirrhotic patients with variceal bleeding, reports a study presented at EASL 2023.

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

20 Jul 2023

Resmetirom delivers improved outcomes for NASH patients with fibrosis

19 Jul 2023 by

The THR-β selective agonist resmetirom helps resolve nonalcoholic steatohepatitis (NASH) and reduce fibrosis, with the drug being safe and well-tolerated, according to data from the large phase III pivotal MAESTRO-NASH trial presented at EASL 2023.